Phospholipase A₂ inhibitors protect against prion and Aβ mediated synapse degeneration

Clive Bate*,1, Mourad Tayebi1 and Alun Williams1,2

Abstract

Background: An early event in the neuropathology of prion and Alzheimer’s diseases is the loss of synapses and a corresponding reduction in the level of synaptophysin, a pre-synaptic membrane protein essential for neurotransmission. The molecular mechanisms involved in synapse degeneration in these diseases are poorly understood. In this study the process of synapse degeneration was investigated by measuring the synaptophysin content of cultured neurones incubated with the prion derived peptide (PrP82-146) or with Aβ1-42, a peptide thought to trigger pathogenesis in Alzheimer’s disease. A pharmacological approach was used to screen cell signalling pathways involved in synapse degeneration.

Results: Pre-treatment with phospholipase A₂ inhibitors (AACOCF₃, MAFP and aristolochic acids) protected against synapse degeneration in cultured cortical and hippocampal neurones incubated with PrP82-146 or Aβ1-42. Synapse degeneration was also observed following the addition of a specific phospholipase A₂ activating peptide (PLAP) and the addition of PrP82-146 or Aβ1-42 activated cytoplasmic phospholipase A₂ within synapses. Activation of phospholipase A₂ is the first step in the generation of platelet-activating factor (PAF) and PAF receptor antagonists (ginkgolide B, Hexa-PAF and CV6029) protected against synapse degeneration induced by PrP82-146, Aβ1-42 and PLAP. PAF facilitated the production of prostaglandin E₂, which also caused synapse degeneration and pre-treatment with the prostanoid E receptor antagonist AH13205 protected against PrP82-146, Aβ1-42 and PAF induced synapse degeneration.

Conclusions: Our results are consistent with the hypothesis that PrP82-146 and Aβ1-42 trigger abnormal activation of cytoplasmic phospholipase A₂ resident within synapses, resulting in elevated levels of PAF and prostaglandin E₂ that cause synapse degeneration. Inhibitors of this pathway that can cross the blood brain barrier may protect against the synapse degeneration seen during Alzheimer’s or prion diseases.

Background

In the transmissible spongiform encephalopathies, otherwise known as the prion diseases, changes in synaptic function and a reduction in synaptophysin levels within the brain occur at a time before any gross neuronal loss is observed [1-3]. These synaptic alterations are associated with the accumulation of a differentially folded, and protease-resistant isoform (PrPSc), of the host encoded cellular prion protein (PrPc) [4]. The formation of PrPSc is accompanied by a decreased expression of proteins involved in exocytosis and neurotransmission, such as synaptophysin, SNAP-25 and synapsins in the brains of scrapie-infected mice [2,5] and in humans affected with Creutzfeldt-Jakob disease (CJD) [6]. The molecular mechanisms that underlie synapse degeneration in prion diseases are not understood. Such processes have been examined by incubating cultured neurones with PrPSc or specific prion-derived peptides. A major PrP fragment spanning amino acid residues 81-82 to 144-153 was isolated from the brains of patients with the hereditary prion disease Gerstmann-Sträussler-Scheinker disease [7]. Synthetic peptides containing amino acid residues 82 to 146 (PrP82-146) had similar structural and biochemical properties to PrPSc suggesting that this
fragment was the neurotoxic species generated in prion
diseases. This hypothesis was strengthened by observa-
tions that both partially purified PrPSc preparations and
PrP82-146 caused synapse degeneration in cortical and
hippocampal neurones [8]. The effect of PrP82-146 on
synapses in neuronal cultures was measured using an
enzyme linked immunosassay (ELISA) to quantify the
amount of synaptophysin [9]. Synaptophysin is a pre-syn-
aptic membrane protein essential for neurotransmitter
release and the recycling of synaptic vesicles and hence
neurotransmission [10-13]. The amount of synaptophysin
has been used to access synaptic density in the brain
[14,15] and in cultured neurones [8]. Although immuno-
cytochemistry is commonly used to examine synapse
density this method is susceptible to errors in counting
and field selection. The use of an ELISA overcome such
problems by measuring synaptic density throughout neu-
ronal cultures.

Synaptic failure is also thought to contribute to the neu-
ropathogenesis of Alzheimer’s disease (AD) [16] and the
loss of synaptic proteins is the best correlate of dementia
in AD [14,17-20]. The amyloid hypothesis of AD patho-
genesis maintains that the primary event is the produc-
tion of neurotoxic amyloid-β (Aβ) peptides following the
proetolytic cleavage of the amyloid precursor protein into
different fragments [21,22]. These fragments include Aβ1-
42 which is widely regarded as the main pathogenic spec-
ies in AD. Recent studies showed the importance of
small soluble oligomers of Aβ or Aβ derived diffusible
ligands in neurotoxicity [23,24].

**Results**

**PLA2 inhibitors protected against PrP82-146 induced
synapse degeneration**

The addition of the prion derived peptide PrP82-146
reduced the synaptophysin content of cortical neurones
indicative of a loss of synapses. This effect was a conse-
quence of the specific amino acid sequence of PrP82-146
as a control peptide (PrP82-146scram) did not affect syn-
apses [8]. The synaptophysin content was reduced by
greater than 80% by 1 μM PrP82-146 (Figure 1A) which
did not affect neuronal survival as measured by thiazyl
blue tetrazolium (98% neuronal survival ± 6 compared
with 100% ± 6, n = 9, P = 0.53). Immunoblot analysis
showed that PrP82-146 caused a dose-related reduction
in the amounts of synaptophysin in cell extracts without
affecting the amounts of β-actin (Figure 1B).

To determine if the degeneration of synapses resulted
from activation of specific cell signalling pathways corti-
cal neurones were pre-treated with inhibitors of some
common cell signalling pathways and incubated with
PrP82-146. Pre-treatment with the PLA2 inhibitors (1 μM
AACOCF3, 1 μM MAFP or 5 μg/ml aristolochic acids)
protected against the PrP82-146 mediated decrease in
synaptophysin (Figure 1A). The concentration of PrP82-
146 required to reduce the synaptophysin content of
vehicle treated cortical neurones by 50% (EC50) was
approximately 60 nM. By comparison, the EC50 of PrP82-
146 for cortical neurones treated with 1 μM AACOCF3 or
1 μM MAFP was greater than 10 μM, and in neurones

![Figure 1 PLA2 inhibitors protected cortical neurones against
PrP82-146 induced synapse degeneration](image-url)
pre-treated with 5 μg/ml aristolochic acids the EC_{50} was 5 μM. In contrast, pre-treatment with phospholipase C inhibitors (10 μM U73122 or ethyl-18-OCH_3) did not affect the PrP82-146 induced loss of synaptophysin from cortical neurones. The synaptophysin content of neurones was not significantly affected by treatment with 5 μM AACOCF_3 (100 units synaptophysin ± 4 compared to 101 ± 4, n = 12, P = 0.5), 5 μM MAFP (100 ± 4 v 102 ± 6, n = 12, P = 0.4) or 5 μg/ml aristolochic acids (100 ± 4 compared to 98 ± 4, n = 12, P = 0.2) alone showing that these drugs did not stimulate synaptogenesis, nor did they damage synapses.

**PLA₂ inhibitors protected hippocampal neurones against PrP82-146 induced synapse degeneration**

To determine if the effect of PLA₂ inhibitors was selective for cortical neurones, their effect on hippocampal neurones was also examined. PrP82-146 reduced the amount of synaptophysin in hippocampal neurones; the EC_{50} of PrP82-146 in hippocampal neurones was 10 nM and while the addition of 200 nM PrP82-146 reduced the synaptophysin content to 20% of control cultures, it did not alter cell survival as measured by thiazyl blue tetrazolium (97% cell survival ± 7 compared with 100% ± 9, n = 9, P = 0.7). Pre-treatment with 1 μM AACOCF_3 or 1 μM MAFP prevented the PrP82-146 mediated decrease in the synaptophysin content of hippocampal neurones and in treated neurones the EC_{50} was increased to greater than 1 μM (Figure 2).

**PLA₂ inhibitors protected against synapse degeneration induced by Aβ₁₋₄₂**

The synapse degeneration that occurs in AD is thought to be caused by Aβ₁₋₄₂ [25,26]. This process can be modelled in vitro and the addition of Aβ₁₋₄₂, but not Aβ₄₂₋₁, reduced the synaptophysin content of cultured cortical and hippocampal neurones [27]. Here we report that pre-treatment with 1 μM AACOCF_3 or 1 μM MAFP protected cortical neurones against the Aβ₁₋₄₂ induced reduction in synaptophysin content (Figure 3A). While the EC_{50} of Aβ₁₋₄₂ in vehicle treated cortical neurones was 50 nM, the EC_{50} of Aβ₁₋₄₂ for cortical neurones treated with 1 μM

---

**Figure 3 PLA₂ inhibitors protected against Aβ₁₋₄₂ induced synapse degeneration**

(A) The synaptophysin content of cortical neurones pre-treated with a vehicle control (■), 1 μM AACOCF_3 (○) or 1 μM MAFP (●) and incubated with varying concentrations of Aβ₁₋₄₂ for 24 hours. Values shown are the mean average amount of synaptophysin ± SD, n = 12. (B) The synaptophysin content of hippocampal neurones pre-treated with a vehicle control (■) or 1 μM AACOCF_3 (○) and incubated with varying concentrations of Aβ₁₋₄₂ for 24 hours. Values shown are the mean average amount of synaptophysin ± SD, n = 6.
AACOCF₃ was greater than 10 μM. PLA₂ inhibitors also protected hippocampal neurones against Aβ₁-₄₂ induced synapse degeneration. Thus, the EC₅₀ of Aβ₁-₄₂ for vehicle treated hippocampal neurones was 10 nM, while in hippocampal neurones pre-treated with 1 μM AACOCF₃ the EC₅₀ of Aβ₁-₄₂ was increased to greater than 1 μM (Figure 3B).

Conditioned medium from 7PA2 cells (7PA2-CM), which contains naturally secreted Aβ oligomers [28], also reduced the synaptophysin content of cortical neurones, whereas conditioned medium from non-transfected Chinese hamster ovary cells (CHO-CM), which did not contain Aβ oligomers, had no affect (Figure 4A). Pretreatment of cortical neurones with either 1 μM AACOCF₃ or 1 μM MAFP prevented the 7PA2-CM mediated decrease in synaptophysin (Figure 4B).

**PLA₂ inhibitors did not affect the accumulation of PrP82-146 in synapses**

Prior studies showed that PrP82-146 accumulated within synaptosomes isolated from cortical neurones prior to synaptic degeneration [8]. That observation raised the possibility that the protective effect of PLA₂ inhibitors might be because they reduced the binding/accumulation of PrP82-146 within synapses. Firstly, we showed that the amount of synaptophysin was not significantly different between synaptosomes isolated from cortical neurones and neurones treated 1 μM AACOCF₃ or 1 μM MAFP; indicating that these drugs did not affect synapse formation. Next cortical neurones were pre-treated with 1 μM AACOCF₃ before the addition of 100 nM PrP82-146. The amount of PrP82-146 found within synaptosomes isolated from vehicle and AACOCF₃ treated neurones were not significantly different (Figure 5). Similar results were obtained with synaptosomes from cortical neurones pre-treated with 1 μM MAFP indicating that the PLA₂ inhibitors did not prevent the binding or transport of PrP82-146 to synapses.

**Figure 4** PLA₂ inhibitors protected against 7PA2-CM induced synapse degeneration. (A) The synaptophysin content of cortical neurones incubated for 24 hours with 7PA2-CM (□) or CHO-CM (■). Values shown are the mean average amount of synaptophysin ± SD, n = 12. (B) The synaptophysin content of cortical neurones incubated for pre-treated with a vehicle control (□), 1 μM AACOCF₃ (■) or 1 μM MAFP (striped bars) and incubated with doubling dilutions of 7PA2-CM for 24 hours. Values shown are the mean average amount of synaptophysin ± SD, n = 12.

**Figure 5** PLA₂ inhibitors did not affect the accumulation of PrP82-146 in synapses. The amount of PrP82-146 detected in synaptosomes isolated from cortical neurones incubated with a vehicle control (■), 1 μM AACOCF₃ (□) or 1 μM MAFP (striped bars). Treated cortical neurones were incubated with 100 nM PrP82-146 for the time periods shown. Synaptosomes were isolated from neuronal cultures and the amount of PrP82-146 was measured by ELISA. Values shown are the mean average amount of PrP82-146 (nM) ± SD, n = 9.
PLA2 inhibitors protected against synapse degeneration induced by PLAP

Next we sought to determine whether synapse degeneration resulted from activation of an endogenous PLA2. The addition of PLAP, a peptide that activated endogenous cPLA2 [29,30], had similar effects as PrP82-146 and Aβ1-42 on synapses; it reduced the synaptophysin content of cortical neurones in a dose dependent manner. The addition of 1 μM PLAP reduced the synaptophysin content of cultured neurones by approximately 80% without affecting the survival of neurones as measured by thiazyl blue tetrazolium (96% neuronal survival ± 5 compared with 100% ± 8, n = 9, P = 0.7). Pre-treatment with 1 μM AACOCF3 or 1 μM MAFP protected cortical neurones against PLAP induced synapse degeneration; in vehicle treated neurones the EC50 of PLAP was 100 nM, while in neurones pre-treated with 1 μM AACOCF3 or 1 μM MAFP the addition of 1 μM PLAP did not reduce the synaptophysin content by more than 20% (Figure 6).

cPLA2 is enriched in synaptosomes

To investigate the hypothesis that synapse degeneration resulted from activation of an endogenous cPLA2, the amount of cPLA2 protein in synaptosomes was measured. The cPLA2 protein was enriched in synaptosomes isolated from cortical neurones compared to whole cell membrane extracts (100 units cPLA2/mg protein ± 31 compared to 6 units/mg ± 1, n = 12, P < 0.01). There were no significant differences in the amount of total cPLA2 protein in synaptosomes isolated from vehicle treated cortical neurones and those treated for 1 hour with 200 nM PrP82-146, 200 nM PrP82-146scrambled, 1 μM PLAP, 100 nM Aβ1-42 or 100 nM Aβ42-1 (Table 1). Measurements were made after 1 hour, before any synapse degeneration was observed. Next specific antibodies (to cPLA2 phosphorylated at serine 505) were used to determine the amount of activated cPLA2 within synaptosomes. The amount of activated cPLA2 within synaptosomes was significantly increased following the addition of 200 nM PrP82-146, 1 μM PLAP or 100 nM Aβ1-42, but not after the addition of PrP82-146scrambled or Aβ42-1 (Table 1). Moreover, there was a significant inverse correlation between the amount of activated cPLA2 in synaptosomes after 1 hour and the amount of synaptophysin in neurones after 24 hours following the addition of different amounts of PrP82-146 (range 1.25 to .005 μM), Pearson’s coefficient = -0.76, P < 0.01 (Figure 7).

PAF antagonists protected against PrP82-146 induced synapse degeneration

The activation of PLA2 is the first step in the production of PAF [31] that has been shown to cause synapse degeneration in vitro [27]. The addition of PAF receptor antagonists (Hexa-PAF, CV6209 or ginkgolide B), in the range 0.1-10 μM, did not affect the amount of synaptophysin in cortical neurones. However, pre-treatment with 2 μM Hexa-PAF, 2 μM CV6209 or 1 μM ginkgolide B provided protection against PrP82-146 induced synapse degeneration (Figure 8). The EC50 of PrP82-146 in vehicle treated cortical neurones was 50 nM while the EC50 of PrP82-146 for neurones treated with 2 μM Hexa-PAF was 2 μM, for neurones treated with 2 μM CV6209 the EC50 was 5 μM and for neurones pre-treated with 1 μM ginkgolide B the EC50 was 20 μM. Pre-treatment with Hexa-PAF, ginkgolide or CV6209 also prevented the reduction in the synaptophysin content of cortical neurones incubated with 100 nM Aβ1-42 or 1 μM PLAP (Table 2). In a similar manner, the amount of synaptophysin in hippocampal neurones incubated with 50 nM PrP82-146 was significantly increased by pre-treatment with 1 μM ginkgolide B (97 units synaptophysin ± 9 compared to 18 ± 7, n = 6, P < 0.01), 2 μM Hexa-PAF (94 ± 11 compared to 18 ± 7, n = 6, P < 0.01) or 2 μM CV6209 (94 ± 11 compared to 18 ± 7, n = 6, P < 0.01).

Prostaglandin E2 induced synapse degeneration

Prior studies showed that PAF facilitates the production of prostaglandins [32] suggesting that one or more of the prostaglandins produced in response to PrP82-146, Aβ1.
42 or PLAP are responsible for synapse degeneration. This hypothesis was tested by treating cortical neurones with individual prostaglandins. We report that the addition of prostaglandin E2, but not other prostaglandins reduced the amount of synaptophysin in cortical neurones (Figure 9). Prostaglandin E2 acts via specific prostanoid E receptors [33] and pre-treatment with the prostanoid E receptor antagonist AH13205, but not the prostanoid D receptor antagonist BW A868C, prevented the loss of synaptophysin in cortical neurones incubated with PrP82-146, Aβ1-42, PLAP or prostaglandin E2 (Table 3). Taken together, these results show that the effects of PrP82-146 or Aβ1-42 on synapses were ultimately mediated through prostanoid E receptors.

**Table 1: PrP82-146 and Aβ1-42 activated cPLA2 within synapses.**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Total cPLA2 protein (units/mg protein)</th>
<th>Activated cPLA2 (units/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None (units)</td>
<td>100 ± 31</td>
<td>100 ± 19</td>
</tr>
<tr>
<td>200 nM PrP82-146</td>
<td>106 ± 18</td>
<td>773 ± 51 *</td>
</tr>
<tr>
<td>200 nM PrP82-146 scrambled</td>
<td>95 ± 22</td>
<td>111 ± 34</td>
</tr>
<tr>
<td>1 μM PLAP</td>
<td>119 ± 30</td>
<td>928 ± 84 *</td>
</tr>
<tr>
<td>100 nM Aβ1-42</td>
<td>109 ± 21</td>
<td>655 ± 62 *</td>
</tr>
<tr>
<td>100 nM Aβ42-1</td>
<td>92 ± 27</td>
<td>121 ± 34</td>
</tr>
</tbody>
</table>

Primary cortical neurones were incubated with PrP, Aβ or PLAP peptides as shown for 1 hour. Synaptosomes were subsequently isolated from treated neurones and the amount of cPLA2 protein, and the amount of activated cPLA2 (phosphorylated at serine 505) were measured by ELISA. Values shown are the mean average amount of cPLA2 protein or activated cPLA2 (units/mg protein) ± SD, n = 12. * = amount of activated cPLA2 significantly greater than in control synaptosomes.

**Discussion**

The addition of PrP82-146 reduced the synaptophysin content of cortical neurones indicative of a loss of synapses. This occurred at concentrations of peptide that did not affect neuronal survival [8], results consistent with in vivo observations that the loss of synapses in prion diseases occurs before any significant neuronal death is seen [1,2]. PrP82-146 also damaged synapses in hippocampal neuronal cultures. The hippocampus is involved in memory formation and the loss of synapses in this area is consistent with the cognitive deficits that occur during the early stages of scrapie infections [3,34].

A pharmacological approach was used to examine the molecular mechanisms involved in prion induced synapse degeneration. Critically, pre-treatment with selective PLA2 inhibitors reduced PrP82-146 induced synapse degeneration, whereas pre-treatment with inhibitors of some other common cell signalling pathways including phospholipase C had no effect. PrPSc is detected within synapses in CJD patients and experimental scrapie infections [2,35,36] and PrP82-146 was found within synaptosomes isolated from cultured neurones [8]. We found that pre-treatment with PLA2 inhibitors did not alter the
amount of PrP82-146 found within synaptosomes, indicating the protective effect of these drugs was not due to the reduced binding of PrP82-146 to synaptic receptors, or a reduction in the trafficking of PrP82-146 to synapses.

Next, the possibility that PrP82-146 might activate cPLA2 resident within synapses was examined. Previous studies reported that PLA2 was found at synapse and regulated synaptic vesicle recycling [37,38] and we observed that cPLA2 was highly enriched in synaptosomes. These observations imply that cPLA2 is part of the normal function of synapses and complete inhibition of cPLA2 may not be desirable as it may interfere with neurotransmission. However, the addition of PrP82-146 increased the amount of activated cPLA2 within synaptosomes nearly 8 fold suggesting that PrP82-146 induced activation of cPLA2 within synapses was responsible for synapse degeneration. This hypothesis was supported by our observations that there was a significant inverse correlation between the amount of activated cPLA2 and synaptic density and that synapse degeneration was also observed after the addition of PLAP. In addition, the effect of both PLAP and PrP82-146 on synapses was greatly reduced by pre-treatment with the cPLA2 inhibitors AACOCF3 and MAFP. Collectively, these results strongly suggesting that activation of an endogenous cPLA2 is a pivotal event in PrP82-146 mediated synapse degeneration.

The activation of PLA2 leads to the formation of a number of bioactive factors including prostaglandins, leukotrienes, docosanoids and PAF [31,39]. PAF receptors are present at synaptic endings [40] and PAF facilitates neurotransmission [41]. However, higher concentrations of PAF are implicated in the neurotoxicity of glutamate, human immunodeficiency virus infection, prion diseases and AD [39,42]. Reports that synaptic activity becomes excitotoxic in neurones exposed to elevated levels of PAF [43] may explain the role of PAF in these diseases. Here we showed that synapse degeneration induced by PrP82-146 was reduced by pre-treatment with PAF receptor antagonists, ginkgolide B, Hexa-PAF and CV6209. These PAF receptor antagonists also reduced synapse degeneration induced by PLAP suggesting that the effect of PrP82-146 and PLAP were a secondary effect mediated by activation of an endogenous cPLA2 and the production of PAF.

PAF affects the production of prostaglandin E2 [32] which is found in close association with PrPSc deposition and neuronal degeneration in scrapie [44]. In addition, the levels of prostaglandin E2 are raised in the cerebrospinal fluid of patients with CJD [45]. While prostaglandin

### Table 2: PAF receptor antagonists reduced synapse degeneration induced by Aβ1-42 or PLAP.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Vehicle</th>
<th>Hexa-PAF</th>
<th>Ginkgolide B</th>
<th>CV6209</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td>100 ± 6</td>
<td>98 ± 7</td>
<td>102 ± 5</td>
<td>96 ± 8</td>
</tr>
<tr>
<td>100 nM Aβ1-42</td>
<td>32 ± 6</td>
<td>94 ± 6</td>
<td>98 ± 9</td>
<td>89 ± 8</td>
</tr>
<tr>
<td>1 μM PLAP</td>
<td>27 ± 7</td>
<td>95 ± 8</td>
<td>94 ± 8</td>
<td>82 ± 7</td>
</tr>
</tbody>
</table>

Primary cortical neurones were pre-treated with a vehicle control, or with PAF receptor antagonists (2 μM Hexa-PAF, 1 μM ginkgolide or 2 μM CV6209) for 1 hour prior to incubation with Aβ1-42 or PLAP as shown for 24 hours. Values shown are the mean average amount of synaptophysin (units/10⁶ cells) ± SD, n = 12.
E2 may modify hippocampal synaptic transmission via a pre-synaptic prostanoid E receptors [46], higher concentrations cause synapse degeneration [27]. As shown in Figure 9 the addition of prostaglandin E2, but not other prostaglandins, caused synapse degeneration. The effects of prostaglandin E2 are mediated by specific membrane bound prostanoid E receptors [47] and synapse degeneration induced by PrP82-146 was reduced by pre-treatment with the prostanoid E receptor antagonist AH13205 suggesting that its effect was mediated through the prostanoid E receptor.

The results presented here may also be pertinent for other diseases in which synapse degeneration is common. For example, the neurotoxicity of Aβ1-42, widely believed to be the main toxin responsible for neurodegeneration in AD [23,48-50], was reduced following knockdown on cPLA2 [51,52]. In this study we showed that Aβ1-42 strongly activated cPLA2 within synapses and that pretreatment with PLA2 inhibitors protected against the synapse degeneration induced by Aβ1-42 and naturally secreted Aβ oligomers (7PA2-CM). This observation is consistent with reports that inhibition of cPLA2 protected against cognitive impairment in a mouse model of AD [53]. A recent study indicated that PrPC acts as a receptor for Aβ1-42 oligomers [54]. PrPC also acts as a receptor for PrP peptides [55] suggesting that both PrP and Aβ1-42 activate PLA2 through their interaction with PrPC. We note that oligomers, rather than monomers, of PrP or Aβ1-42 are neurotoxic [56-58]. Since oligomers of PrP and Aβ1-42, but not monomers, have the capacity to cross-link PrPC, our results support the hypothesis that it is the cross-linkage of PrPC by PrP or Aβ1-42 oligomers that activated cPLA2 leading to the production of PAF and prostaglandins. We propose that it is the persistent activation of cPLA2 by PrP82-146 or Aβ1-42 that results in high concen-

### Table 3: A prostanoid E receptor antagonist protected against synapse degeneration

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Vehicle control</th>
<th>Prostanoid E receptor antagonist AH13205</th>
<th>Prostanoid D receptor antagonist BWA868C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle control</td>
<td>100 ± 6</td>
<td>99 ± 7</td>
<td>99 ± 3</td>
</tr>
<tr>
<td>200 nM PrP82-146</td>
<td>22 ± 5</td>
<td>87 ± 8</td>
<td>30 ± 7</td>
</tr>
<tr>
<td>100 nM Aβ1-42</td>
<td>32 ± 6</td>
<td>93 ± 5</td>
<td>34 ± 6</td>
</tr>
<tr>
<td>1 μM PLAP</td>
<td>27 ± 7</td>
<td>91 ± 7</td>
<td>38 ± 6</td>
</tr>
<tr>
<td>10 nM PAF</td>
<td>31 ± 4</td>
<td>85 ± 9</td>
<td>32 ± 5</td>
</tr>
<tr>
<td>10 nM Prostaglandin E2</td>
<td>30 ± 5</td>
<td>97 ± 3</td>
<td>33 ± 6</td>
</tr>
</tbody>
</table>

Primary cortical neurones were pre-treated with a vehicle control, a prostanoid E receptor antagonist (100 nM AH13205) or a prostanoid D receptor antagonist (100 nM BWA868C) for 1 hour prior to incubation with PrP82-146, Aβ1-42, PLAP, PAF or prostaglandin E2 as shown for 24 hours. Values shown are the mean average amount of synaptophysin ± SD, n = 9.

![Figure 9 Prostaglandin E2 caused synapse degeneration](image)
trations of PAF and prostaglandin E₂ that cause synapse degeneration [27,43].

**Conclusion**

Drugs that protect the synapse provide a rational strategy to treat many neurodegenerative diseases. In this study we showed that PLA₂ inhibitors, PAF receptor antagonists and a prostanoid E receptor antagonist all protected against the synapse degeneration induced by PrP82-146 or Aβ1-42 in vitro. These peptides did not have a direct effect on synapses; rather synapse degeneration was caused after PrP82-146 or Aβ1-42 induced activation of an endogenous cPLA₂ and the production of PAF and prostaglandin E₂. Such results suggest that specific cPLA₂ inhibitors or PAF receptor antagonists that are able to cross the blood-brain barrier should be considered for further testing in animal models of prion and Alzheimer’s diseases.

**Methods**

**Primary neuronal cultures**

Primary cortical neurones were prepared from the brains of mouse embryos (day 15.5). Neuronal precursors were plated at 2 × 10⁵ cells/well in 48 well plates in Ham’s F12 containing 5% foetal calf serum (FCS) for 2 hours. Cultures were shaken (600 r.p.m for 5 minutes) and non-adherent cells removed by 3 washes in phosphate buffered saline (PBS). Neurones were grown in neurobasal medium (NBM) containing B27 components (PAA) for 7 days. Immunohistochemistry showed that the cells were greater than 97% neurofilament positive. Less than 3% stained for GFAP (astrocytes) or for F4/80 (microglial cells). Hippocampal neurones were prepared from the brains of adult mice as described [59]. Briefly, hippocampi were dissected and triturated in Ham’s F12 containing 5% FCS, 0.35% glucose, 0.025% trypsin, and 0.1% type IV collagenase. After 30 minutes at 37°C, the cells were triturated again and the cell suspension was passed through a 100 μM cell strainer. Cells were collected by centrifugation, washed twice in Ham’s F12 containing 5% FCS and plated at 2 × 10⁵ cells/well in 48 well plates for 24 hours. Cultures were shaken (600 r.p.m for 5 minutes) to remove non-adherent cells, washed twice with PBS and neurones were cultured in NBM containing B27 components and 10 ng/ml glial-derived neurotrophic factor (Sigma) for 10 days. Neurones were incubated with test compounds for 3 hours before the addition of peptides and the amount of synaptophysin in treated neurones was measured 24 hours later. The survival of neurones was determined 5 days later using 25 μM thiazyl blue tetrazo- lium for 3 hours; neuronal survival was reported as a percentage of controls (vehicle treated neurones).

**Cell extracts**

Neurones were homogenised in a buffer containing 150 mM NaCl, 10 mM Tris-HCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate and mixed protease inhibitors (AEBSF, Aprotinin, Leupeptin, Bestain, Pepstatin A and E-46 (Sigma)) and a phosphatase inhibitor cocktail including PP1, PP2A, microcystin LR, cantharidin and p-bromotetramisole (Sigma) at 10⁶ cells/ml.

Nuclei and cell debris was removed by low speed centrifugation (300 × g for 5 minutes). For immunoblots, cells were mixed 1:1 with Laemmlı buffer containing β-mercaptoethanol, boiled for 5 minutes and run on a 12% polyacrylamide gel. Proteins were transferred onto a Hybond-P PVDF membrane (Amersham Biotech) by semi-dry blotting. Membranes were blocked using 10% milk powder; synaptophysin was detected using a mouse monoclonal antibody (mAb) anti-synaptophysin SY38 (Abcam) and β-actin was detected by incubation with a mouse mAb (clone AC-74, Sigma). These were visualised using a combination of biotinylated rabbit anti-mouse IgG (Dako), extravidin-peroxidase and an enhanced chemiluminescence kit (Invitrogen).

**Synaptophysin ELISA**

Synaptophysin levels in cell extracts were measured by ELISA as described [9,27]. A mouse monoclonal anti-synaptophysin MAB368 (Millipore) was used as a capture antibody and bound synaptophysin was detected using rabbit polyclonal antibody (mAb) anti-synaptophysin SY38 (Abcam) and β-actin was detected by incubation with a mouse mAb (clone AC-74, Sigma). Absorbance was measured on a microplate reader at 405 nm and synaptophysin content was calculated from a standard curve. Samples were expressed as "units synaptophysin" where 100 units was defined as the amount of synaptophysin in 10⁶ vehicle treated neurones. A standard curve was generated from this sample using sequential log 2 dilutions (range 100 to 1.56 units).

**Synaptosome preparations**

Cortical neurones were pre-treated with drugs for 3 hours prior to the addition of 100 nM PrP82-146. After different time points (10, 30, 60 or 90 minutes) neurones were washed 3 times to remove unbound peptide and synaptosomes prepared on a discontinuous Percoll gradient as described [60]. Briefly, 10⁶ cortical neurones were homogenized at 4°C in 1 ml of SED solution (0.32 M sucrose, 50 mM Tris-HCl, 1 mM EDTA, and 1 mM dithiothreitol, pH 7.4 and mixed protease/phosphates inhibitors (as above)). The preparation was centrifuged at 1000 × g for 10 minutes. The supernatant was transferred to a 4-step gradient of 3, 7, 15, and 23% Percoll in SED solution and centrifuged at 16,000 × g for 30 minutes at
4°C. The synaptosome fraction was collected from the interface of the 15% and 23% Percoll steps, washed twice (16,000 × g for 30 minutes at 4°C) and suspended in extraction buffer (150 mM NaCl, 10 mM Tris-HCl, 10 mM EDTA, 0.2% SDS and mixed protease/phosphatase inhibitors).

**PrP82-146 ELISA**

The amount of PrP82-146 in synaptosomes was determined by ELISA. Nunc Maxisorb Immunoplates were coated with 0.5 μg/ml of mouse mAb 3F4 (reactive with residues 109-112 of human PrP [Abcam]) this mAb does not bind to murine PrP [61]. Samples were applied and PrP82-146 was detected with 0.5 μg/ml biotinylated ICSM35 (D-gen, http://www.d-gen.co.uk), followed by streptavidin-alkaline phosphatase (Dako) and 1 mg/ml 4-nitrophenyl phosphate (Sigma). Absorbance was measured on a microplate reader at 405 nm and the amount of PrP82-146 in cell extracts was calculated by reference to a standard curve of PrP82-146.

**cPLA2 ELISA**

The amount of cPLA2 in synaptosomes was measured by ELISA [62]. Nunc Maxisorb Immunoplates were coated with 0.5 μg/ml of mouse mAb anti-cPLA2, clone CH-7 (Upstate) and blocked with 10% FCS. Samples were incubated for 1 hour and the amount of cPLA2 was detected using a goat polyclonal anti-cPLA2 (Santa-Cruz Biotech). Bound antibodies were detected with biotinylated anti-goat IgG, extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenyl phosphate. Absorbance was measured at 405 nm and the amount of cPLA2 was calculated from a standard curve using nonlinear regression. The amount of cPLA2 protein was expressed in units (100 units = amount of cPLA2 in synaptosomes isolated from 10^6 untreated primary cortical neurones). The activation of cPLA2 is accompanied by phosphorylation of the 505 serine residue which creates a unique epitope. To measure the amount of activated cPLA2, an ELISA using a mAb (anti-cPLA2, clone CH-7) combined with rabbit polyclonal anti-phospho-cPLA2 (Cell Signalling Technology) was used. Bound antibodies were detected with biotinylated anti-rabbit IgG (Dako), extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenyl phosphate. Samples were expressed as "units activated cPLA2" where 100 units were defined as the amount of activated cPLA2 in synaptosomes derived from 10^6 untreated primary cortical neurones.

**Drugs**

U73122 and Ethyl-18-OCH_3 were obtained from Biomol. Arachidonyl trifluoromethyl ketone (AACOCF_3), aristo-

**List of abbreviations**

(AD): Alzheimer’s disease; (Aβ): amyloid-β; (AACOCF_3): Arachidonyl trifluoromethyl ketone; (CHO): Chinese hamster ovary; (CM): conditioned medium; (CJD): Creutzfeldt-Jakob disease; (DMSO): di-methyl sulphoxide; (ELISA): Enzyme linked immunoassay; (Hexa-PAF): 1-O-Hexadecyl-2-acetyl-sn-glycerol-3-phospho-(N,N,N-trimethyl)-hexanolamine; (MAFP): methyl arachidonyl fluorophosphonate; (NBM): neurobasal medium; (PBS): phosphate buffered saline; (PLA2): phospholipase A_2; (cPLA2): cytoplasmic PLA_2; (PLAP): PLA_2 Activating...
Peptide; (PAF): platelet-activating factor; (PrP): prion protein.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
CB and MT were responsible for the conception, planning and performance of experiments and for writing the manuscript. AW contributed to the planning of experiments, interpretation of results and the writing of the manuscript. All authors approved the final manuscript.

Acknowledgements
This work was supported by the European Community FPs “Neuropion” Network of Excellence. We thank Professor Mario Saloma (Milan) for supplying PrPβ2-146 and PrPβ2-146Scrambled peptides.

Author Details
1. Department of Pathology and Infectious Diseases, Royal Veterinary College, Hawkshead Lane, North Mymms, Herts, AL9 7TA, UK and 2. Department of Veterinary Medicine, University of Cambridge, Madingely Road, Cambridge, CB3 OES, UK

Received: 27 January 2010 Accepted: 8 April 2010
Published: 8 April 2010

References
synaptic structures of the central nervous system in patients with Creutzfeldt-Jakob disease.


Cite this article as: Bate et al., Phospholipase A2 inhibitors protect against prion and A\(_\beta\) mediated synapse degeneration *Molecular Neurodegeneration* 2010, 5:13.
Author/s: Bate, C; Tayebi, M; Williams, A

Title: Phospholipase lipase A(2) inhibitors protect against prion and A beta mediated synapse degeneration

Date: 2010-04-08


Persistent Link: http://hdl.handle.net/11343/258961

File Description: Published version

License: CC BY